Newsroom

Fibrocell to Present at Inaugural Cell & Gene Exchange 2017

2 weeks ago

EXTON, Pa., May 17, 2017 (GLOBE NEWSWIRE) — Fibrocell Science, Inc. (FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that John Maslowski, Chief Executive Officer, will present at the inaugural Cell & Gene Exchange 2017 on Monday, May 22 at 2:00 pm EDT at the Ronald Reagan Building in Washington, D.C. In addition, Mr. Maslowski will participate in a roundtable discussion, “Best Practices for Partnering with Disease Foundations and Patient Groups,” on Monday, May 22 at 3:15 p.m. EDT.

A live webcast of Mr. Maslowski’s presentation and the roundtable discussion will be available under the investor relations section of Fibrocell’s website at www.fibrocell.com/investors/events and archived for 30 days.

Co-produced by the Alliance for Regenerative Medicine and the EBD Group and held in partnership with Global Genes, this event is the only partnering conference that brings together the regulatory, business and patient advocacy communities across the cell and gene therapy sectors.

About Fibrocell

Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell’s most advanced product candidate, FCX-007, is the subject of a Phase 1/2 clinical trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is in pre-clinical development of FCX-013, its product candidate for the treatment of linear scleroderma. Fibrocell’s gene therapy portfolio is being developed in collaboration with Intrexon Corporation (XON), a leader in synthetic biology. For more information, visit http://www.fibrocell.com or follow Fibrocell on Twitter at @Fibrocell.

Stock Information

Investor Toolkit

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address